Assessing Baxter International’s Valuation After Earnings Beat And Guidance Reaffirmation

Why Baxter International (BAX) is back on investors’ radar

Baxter International (BAX) moved back into focus after first quarter results topped revenue and non GAAP profit expectations, management reiterated full year earnings guidance, and analysts responded with more constructive commentary on the stock.

See our latest analysis for Baxter International.

The better than expected first quarter and reaffirmed full year earnings guidance came after a tough stretch for shareholders, with a 90 day share price return of a 20.35% decline and a 1 year total shareholder return of a 43.27% loss, suggesting momentum has been weak despite the recent bounce.

If Baxter's recent earnings have you reassessing your watchlist, it may be worth widening your search with our screener for 35 healthcare AI stocks

With Baxter stock still well below recent levels and trading at what some analysts see as a discount to both their price targets and certain intrinsic estimates, you need to decide: is this a reset buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 23% Undervalued

At a last close of $16.75 versus a narrative fair value of $21.63, Baxter is framed as undervalued, with that gap hinging on future margin repair.

Ongoing portfolio optimization efforts, including divestitures, cost reductions, and a commitment to eliminate stranded costs by 2027, aim to streamline operations, improve efficiency, and drive net margin improvement, which should be reflected in future earnings growth.

Read the complete narrative.

Want to see what revenue trajectory, margin rebuild, and future earnings multiple have to look like to support that valuation gap? The full narrative walks through those assumptions in detail.

Result: Fair Value of $21.63 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you also need to factor in risks such as ongoing margin pressure and quality or legal issues around products like Novum IQ, which could challenge this thesis.

Find out about the key risks to this Baxter International narrative.

Next Steps

With the mixed sentiment in this article, it makes sense to move quickly, review the data for yourself, and see both sides through 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If Baxter has you rethinking your portfolio, do not stop here. Broaden your opportunity set with a few focused stock lists that many investors overlook.

• Target potential mispricing by scanning through companies our process flags as 51 high quality undervalued stocks.
• Prioritize strength by filtering for businesses on the solid balance sheet and fundamentals stocks screener (45 results).
• Get ahead of the crowd by checking the screener containing 25 high quality undiscovered gems before the wider market catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com